Tonghua Dongbao Pharmaceutical (600867) Fundamentals 2026 — P/E 13.2x, Revenue Analysis | SniperIQ
Tonghua Dongbao Pharmaceutical (600867) is a CN-listed Healthcare company in Drug Manufacturers - General with a market capitalization of ¥16.1B, trading at ¥8.20 on the SHH. This SniperIQ fundamentals page covers Tonghua Dongbao Pharmaceutical's valuation (P/E 13.2x, P/B 2.4x), profitability (net margin 40.6%), revenue (¥2.9B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Tonghua Dongbao Pharmaceutical's market cap?
Tonghua Dongbao Pharmaceutical (600867) has a market capitalization of approximately ¥16.1B, trading at ¥8.20 on the SHH. Market cap moves with the live share price.
What is Tonghua Dongbao Pharmaceutical's P/E ratio?
Tonghua Dongbao Pharmaceutical's trailing twelve-month P/E ratio is 13.2x, with a price-to-book (P/B) of 2.4x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Tonghua Dongbao Pharmaceutical?
Tonghua Dongbao Pharmaceutical runs a net profit margin of 40.6%, a gross margin of 70.9%, and an operating margin of 53.5%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Tonghua Dongbao Pharmaceutical generate?
Tonghua Dongbao Pharmaceutical reported revenue of ¥2.9B for fiscal year 2025, with net income of ¥1.2B and earnings per share (EPS) of 0.62. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Tonghua Dongbao Pharmaceutical pay a dividend?
Tonghua Dongbao Pharmaceutical offers a trailing dividend yield of about 3.7%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is Tonghua Dongbao Pharmaceutical financially healthy?
Tonghua Dongbao Pharmaceutical carries a debt-to-equity ratio of 0.06x and a current ratio of 4.84x, with a market beta of 0.17. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Tonghua Dongbao Pharmaceutical a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Tonghua Dongbao Pharmaceutical (600867) the key facts are: market cap ¥16.1B, P/E 13.2x, revenue ¥2.9B, 52-week range 7.16-10.67. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Tonghua Dongbao Pharmaceutical's full fundamentals live
Get Tonghua Dongbao Pharmaceutical's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.